The product is available for shipping immediately, Cipla said.
Pulmicort Respules and generic equivalents had U.S. sales of approximately $825M for the 12-
month period ending September 2017, making them fairly large in terms of sales.
Budesonide Inhalation Suspension will be launched in three dosages — 0.25mg/2mL, 0.5mg/2mL and 1mg/2mL and are the AN-rated generic equivalents of Astrazeneca’s Pulmicort Respules.
It is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age.
Cipla is present in India as well as across more than 80 countries and sells over 1500 products across wide range of therapeutic categories.